New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial

New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial

A two-week course of antiviral therapy with interferon beta-1b, plus lopinavir-ritonavir and ribavirin, started within seven days of showing COVID-19 symptoms, is safe and more effective at reducing the duration of viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness. That’s according to the first randomized trial of this triple combination therapy […]